Ticagrelor versus clopidogrel in <i>CYP2C19</i> loss-of-function carriers with stroke or TIA stratified by age and renal function: CHANCE-2 trial substudy.

ABSTRACT:

Objective

To compare the efficacy and safety of ticagrelor versus clopidogrel in stroke patients who were CYP2C19 loss-of-function (LOF) carriers stratified by age and renal function.

Methods

Patients in the CHANCE-2 trial were randomized to ticagrelor-aspirin or clopidogrel-aspirin treatment. The primary efficacy outcome was occurrence of a new stroke within 90 days, while bleeding was assessed for safety. Patients were categorized based on age and estimated glomerular filtration rate (eGFR).

Results

In patients with eGFR >90 mL/min/1.73 m², ticagrelor-aspirin was associated with a significantly lower risk of the subsequent stroke within 90 days compared with the clopidogrel-aspirin in those aged over 65 years (HR 0.53, 95% CI 0.33-0.85, p = 

SUBMITTER: Wu Y 

PROVIDER: S-EPMC12288173 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature